Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Res ; 1756: 147280, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33515535

ABSTRACT

PURPOSE: Growing evidence has shown that the stress hormones affect tumor progression. Patients with surgery to remove tumor often have increased norepinephrine during the perioperative period. However, the effect of norepinephrine on the progression of glioblastoma has not yet studied. Therefore, the present study aimed at investigating the effects of norepinephrine on the migration and invasion of the human glioblastoma U87 and U251 cell lines and the mechanism for the effects. METHODS: The U87 and U251 cells were treated with 0, 0.1, 1, 5, 10 or 50 µM norepinephrine. A scratch wound healing assay and a transwell invasion assay were used to investigate cell migration and invasion, respectively. The Human Tumor Metastasis RT2 Profiler PCR Array was used to detect the expression of 84 genes known to be involved in metastasis. RESULTS: Following norepinephrine treatment, the ability of the U87 and U251 cells to migrate and invade was significantly decreased. Human Tumor Metastasis RT2 Profiler PCR Array assay showed that matrix metallopeptidase-11 (MMP-11) was decreased following norepinephrine treatment. The ß-adrenergic receptor blocker (AR) propranolol blunted the suppressive effect of norepinephrine on the migration and invasion of U251 cells but did not have such an effect on the invasion of U87 cells. MMP-11 silencing inhibited the migration and invasion of U87 and U251 cells. The Cancer Genome Atlas data showed that patients with higher expression of MMP-11 in the glioblastoma tissues had poorer prognosis. CONCLUSION: Our results indicate that norepinephrine inhibits the migration and invasion of human glioblastoma cells. This effect may be mediated by the decrease of MMP-11. ß-AR may be a regulatory factor for this effect in U251 cells.


Subject(s)
Cell Movement/drug effects , Glioblastoma/drug therapy , Matrix Metalloproteinase 11/drug effects , Neoplasm Invasiveness/pathology , Norepinephrine/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Glioblastoma/metabolism , Humans , Matrix Metalloproteinase 11/metabolism
2.
Biochim Biophys Acta Proteins Proteom ; 1868(6): 140412, 2020 06.
Article in English | MEDLINE | ID: mdl-32179183

ABSTRACT

Matrix metalloproteinases (MMPs) are zinc-dependent extracellular matrix remodeling endopeptidases. MMPs cleave various matrix proteins such as collagen, elastin, gelatin and casein. MMPs are often implicated in pathological processes, such as cancer progression including metastasis. Meanwhile, microorganisms produce various secondary metabolites having unique structures. We designed and synthesized dehydroxymethylepoxyquinomicin (DHMEQ) based on the structure of epoxyquinomicin C derived from Amycolatopsis as an inhibitor of NF-κB. This compound inhibited cancer cell migration and invasion. Since DHMEQ is comparatively unstable in the body, we designed and synthesized a stable DHMEQ analog, SEMBL. SEMBL also inhibited cancer cell migration and invasion. We also looked for inhibitors of cancer cell migration and invasion from microbial culture filtrates. As a result, we isolated a known compound, ketomycin, from Actinomycetes. DHMEQ, SEMBL, and ketomycin are all NF-κB inhibitors, and inhibited the expression of MMPs in the inhibition of cellular migration and invasion. These are all compounds with comparatively low toxicity, and may be useful for the development of anti-metastasis agents.


Subject(s)
Antineoplastic Agents/pharmacology , Benzamides/antagonists & inhibitors , Cyclohexanones/antagonists & inhibitors , Matrix Metalloproteinases/drug effects , Matrix Metalloproteinases/metabolism , NF-kappa B/drug effects , NF-kappa B/metabolism , Actinobacteria/metabolism , Animals , Antineoplastic Agents/chemistry , Benzamides/chemical synthesis , Benzamides/chemistry , Cell Line, Tumor , Cell Movement/drug effects , Cyclohexanones/chemical synthesis , Glyoxylates/antagonists & inhibitors , Glyoxylates/metabolism , Humans , Matrix Metalloproteinase 11/drug effects , Matrix Metalloproteinase 11/metabolism , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/drug effects , Matrix Metalloproteinase 9/metabolism , Models, Molecular , NF-kappa B p50 Subunit/metabolism , Neoplasm Invasiveness , Neoplasms , Quinones/chemistry
3.
Arch Oral Biol ; 52(6): 585-90, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17181997

ABSTRACT

OBJECTIVE: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a role in the breakdown of the extracellular matrix during normal physiological processes, and in pathological processes, including periodontitis. The aim of this study was to evaluate the effect of epidermal growth factor (EGF) on the expression of MMPs and TIMPs in cultured human gingival fibroblasts. METHODS: Fibroblasts were stimulated with 10(-3), 10(-6) or 10(-12)M EGF for 24h; untreated fibroblasts served as controls. Alterations in the expression of MMP-1, 2, 3, 7, 11, TIMP-1 and 2 were evaluated using real-time PCR and Western blotting. beta-Actin expression was used as a reference to normalize gene expression. RESULTS: Increased MMP-1, 3, 7 and 11 expressions were observed at all EGF concentrations (p<0.05). At the lowest EGF concentration, MMP-1, 3 and 7 presented the lowest expression and MMP-11 presented the greatest expression; at higher EGF concentrations, MMP-1, 3 and 7 presented greater up-regulation, and MMP-11 lower up-regulation (p<0.05). Protein expression was similarly regulated by EGF: increased up-regulation of MMP-1, 3 and 7 was observed with increasing EGF concentrations, except for MMP-11 that exhibited greater up-regulation at the lower EGF concentration. The gene expression of MMP-2, TIMP-1 and 2 was not affected by EGF (p<0.05). CONCLUSIONS: We conclude that EGF regulates expression for MMP-1, 3, 7 and 11 in a dose-dependent manner, suggesting that EGF may play a role in periodontal destruction and wound repair.


Subject(s)
Epidermal Growth Factor/pharmacology , Fibroblasts/drug effects , Gingiva/drug effects , Matrix Metalloproteinases/drug effects , Tissue Inhibitor of Metalloproteinases/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Fibroblasts/enzymology , Gene Expression Regulation/drug effects , Gingiva/cytology , Gingiva/enzymology , Humans , Matrix Metalloproteinase 1/analysis , Matrix Metalloproteinase 1/drug effects , Matrix Metalloproteinase 11/analysis , Matrix Metalloproteinase 11/drug effects , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 3/analysis , Matrix Metalloproteinase 3/drug effects , Matrix Metalloproteinase 7/analysis , Matrix Metalloproteinase 7/drug effects , Matrix Metalloproteinases/analysis , Tissue Inhibitor of Metalloproteinase-1/analysis , Tissue Inhibitor of Metalloproteinase-1/drug effects , Tissue Inhibitor of Metalloproteinase-2/analysis , Tissue Inhibitor of Metalloproteinase-2/drug effects , Tissue Inhibitor of Metalloproteinases/analysis , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...